Skip to main content Back to Top


Nitrofurantoin Oral Suspension

Products Affected - Description

    • Furadantin oral suspension, Casper, 25 mg/5 mL, 230 mL bottle, NDC 70199-0006-32
    • Nitrofurantoin oral suspension, Amneal, 25 mg/5 mL, 230 mL bottle, UPC 65162-0689-88 - discontinued
    • Nitrofurantoin oral suspension, Lupin, 25 mg/5 mL, 230 mL bottle, UPC 43386-0450-11 - discontinued
    • Nitrofurantoin oral suspension, Teva, 25 mg/5 mL, 230 mL bottle, NDC 00472-1992-08

Reason for the Shortage

    • Casper Pharma stated the Furadantin shortage is due to manufacturing delays.
    • Nostrum has nitrofurantoin oral suspension available.
    • Teva did not provide a reason for the shortage.

Available Products

    • Nitrofurantoin oral suspension, Nostrum, 25 mg/5 mL, 240 mL bottle, NDC 70408-0239-32

Estimated Resupply Dates

    • Casper has nitrofurantoin oral suspension on back order and the company cannot estimate a release date.
    • Teva has nitrofurantoin oral suspension temporarily unavailable and the company cannot estimate a release date.

Alternative Agents & Management

    • Nitrofurantoin 2 mg/mL suspension can be made from nitrofurantoin bulk powder and SyrSpend SF PH4 vehicle. Mix nitrofurantoin with a small amount of suspending vehicle to form a paste. Dilute the paste with additional SyrSpendSF to a final volume of 300 mL. Store at room temperature or under refrigeration in light-resistant bottles. Suspension is stable for 90 days.[1]
    • Macrodantin (nitrofurantoin macrocrystalline) capsules can be opened and mixed with food or water and flushed down a tube.[2]
    • Macrobid (nitrofurantoin monohydrate/macrocrystalline) capsules should not be opened as this may interfere with the nitrofurantoin release mechanism.[2]


    1. De Oliveira, FA, Polonini HC, Loures da Silva S, et al., (2017). Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantion, Ondansetron HCl, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF PH4 Oral Suspensions. International Journal of Pharmaceutical Compounding, 21(3), 255-263.
    2. Alvogen Customer Service (personal communications). June 5, 2018.


Updated October 19, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 5, 2018 by Leslie Jensen, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.



Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.